Cargando…

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

OBJECTIVE: To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy compared with MTX combination with non-biological disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis. METHOD: A systematic review of randomised trials comparing MTX alone and in combina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689526/ https://www.ncbi.nlm.nih.gov/pubmed/19054823 http://dx.doi.org/10.1136/ard.2008.099861

Ejemplares similares

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
por: Zhang, Le, et al.
Publicado: (2020)

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
por: Stohl, William, et al.
Publicado: (2012)

Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
por: Affleck, K., et al.
Publicado: (1992)

Impairment of Methotrexate (MTX)‐Polyglutamate Formation of MTX‐resistant K562 Cell Lines
por: Koizumi, Shoichi
Publicado: (1988)

Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
por: Saito, Shuntaro, et al.
Publicado: (2019)

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
por: Hazlewood, Glen S, et al.
Publicado: (2016)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis
por: Donahue, Katrina E., et al.
Publicado: (2019)

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

LETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side Effects
por: Borman, Pinar, et al.
Publicado: (2014)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients
por: Wajda, Anna, et al.
Publicado: (2021)

Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
por: Zhang, Jing, et al.
Publicado: (2020)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022)

MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
por: Shiozawa, Kazuko, et al.
Publicado: (2016)

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
por: Emery, P, et al.
Publicado: (2010)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study
por: Musdalita, Eva, et al.
Publicado: (2022)

Facile Electrochemical Determination of Methotrexate (MTX) Using Glassy Carbon Electrode-Modified with Electronically Disordered NiO Nanostructures
por: Khand, Aftab A., et al.
Publicado: (2021)

The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)
por: Watanabe, Shiro, et al.
Publicado: (2016)

Complete Genome Sequence of Serratia marcescens Phage MTx
por: Graham, Kristin, et al.
Publicado: (2019)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2021)

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
por: Fleischmann, R, et al.
Publicado: (2008)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein
por: Kuroiwa, Yuki, et al.
Publicado: (2013)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Near-infrared fluorescence imaging-guided focused ultrasound-mediated therapy against Rheumatoid Arthritis by MTX-ICG-loaded iRGD-modified echogenic liposomes
por: Wu, Haohan, et al.
Publicado: (2020)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
por: Hirani, SP, et al.
Publicado: (2008)

Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
por: Deng, Daihua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cdhp5chmoqnclvn1h95iboa46e